Pivotal BE Study of TAH3311 ODF vs ELIQUIS Tablet Under Fasted Condition in Healthy Volunteers
Status:
COMPLETED
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
This single-dose, open-label, randomized, four-way crossover study evaluates the pharmacokinetics, safety, and tolerability of TAH3311 5 mg in healthy volunteers under fasted and fed conditions.